2013-03-01 16:54:57 - New Pharmaceuticals market report from GlobalData: "PharmaPoint: Prostate Cancer - France Drug Forecast and Market Analysis to 2022"
GlobalData has released its new Country report, "PharmaPoint: Prostate Cancer - France Drug Forecast and Market Analysis to 2022". The recent approvals of second-line metastatic castration-resistant prostate cancer (mCRPC) therapies like J&J's Zytiga (abiraterone acetate) and Medivation/Astellas' Xtandi (enzalutamide) will drive strong market growth over the next decade. These safe and orally administered treatments will provide safety and convenience benefits over the current standard of care, chemotherapy with docetaxel, while prolonging the overall survival of patients with mCRPC. The December 12, 2012 FDA approval of Zytiga for the added indication of chemotherapy-naive mCRPC marks the onset of a new treatment paradigm for the disease, in which chemotherapy is relegated to second-line therapy and beyond. For patients with earlier-stage prostate cancer,
androgen deprivation therapy with LHRH agonists and first-generation antiandrogens remains the standard of care for suppressing testosterone levels and temporarily controlling the disease.
Full Report Details at
- www.fastmr.com/prod/544163_pharmapoint_prostate_cancer_france_dr ..
In France, the PSA test and DREs are the most popular diagnostic tests for prostate cancer (EAU, 2012). Routine PSA screening is widely used, although less commonly than in the US. GlobalData's primary research shows that overall, French prescribing physicians do not plan to change their use of PSA screening in response to the recent USPSTF recommendation against routine screening, nor do they expect referring physicians to change their screening patterns. As in most major markets, a diagnosis of prostate cancer in France is confirmed following high PSA levels or other symptoms by multiple core needle biopsies or TRUS, and metastases are diagnosed using bone scans or CT scans (EAU, 2012).
* Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
* Detailed information on the key drugs in France including product description, safety and efficacy profiles as well as a SWOT analysis.
* Sales forecast for the top drugs in France from 2012 to 2022.
* Analysis of the impact of key events as well the drivers and restraints affecting the France Prostate cancer market.
Reasons to buy
* Understand and capitalize by identifying products that are most likely to ensure a robust return
* Stay ahead of the competition by understanding the changing competitive landscape for Prostate cancer
* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
* Make more informed business decisions from insightful and in-depth analysis of Prostate cancer drug performance in France
* Obtain sales forecast from 2012-2022 in France
Partial Table of Contents:
1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.4 Quality of Life
4 Disease Management
4.1 Diagnosis and Referral Overview
4.2 Treatment Overview
4.2.1 Conservative Management Strategies
4.2.2 Localized Treatments
4.2.3 Hormone Therapy
4.2.4 Drug Therapies
4.3.2 Clinical Practice
5 Competitive Assessment
5.2 Strategic Competitor Assessment
5.3 Product Profiles - Major Brands, Hormone Therapies
5.3.1 Zoladex (goserelin acetate)
5.3.2 Lupron Depot (leuprolide acetate)
5.3.3 Eligard (leuprolide acetate)
5.3.4 Trelstar (triptorelin acetate)
5.3.5 Firmagon (degarelix)
5.3.6 Casodex (bicalutamide)
5.4 Product Profiles - Major Brands, Chemotherapies
5.4.1 Taxotere (docetaxel)
5.4.2 Jevtana (cabazitaxel)
5.5 Product Profiles - Major Brands, Therapeutic Vaccines
5.5.1 Provenge (sipuleucil-T)
5.6 Product Profiles - Major Brands, Targeted Therapies
5.6.1 Zytiga (abiraterone acetate)
5.6.2 Xtandi (enzalutamide)
5.7 Product Profiles - Major Brands, Bone Therapies
5.7.1 Xgeva (denosumab)
5.7.2 Zometa (zoledronic acid)
5.8 Other Marketed Hormone and Drug Therapies
6 Opportunity and Unmet Need
6.2 Efficacy at Prolonging Overall Survival
6.4 Mitigation of Symptoms
6.6 Convenient Routes of Administration
6.7 Accurate Diagnostic Tests and Surveillance Tools
6.8 Unmet Needs Gap Analysis
6.9 Opportunity: Targeting Early-Stage, Hormone-Sensitive Prostate Cancer
7 Pipeline Assessment
7.2 Promising Drugs in Clinical Development
7.2.2 Custirsen Sodium
7.2.3 Sprycel (dasatinib)
7.2.4 Yervoy (ipilimumab)
7.2.6 Alpharadin (radium-223 chloride)
7.2.8 ProstVac (Vaccinia-PSA-TRICOM/Fowlpox-PSA-TRICOM)
8 Market Outlook
8.1.2 Key Events
8.1.3 Drivers and Barriers
Full Table of Contents is available at:
GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at www.fastmr.com/catalog/publishers.aspx?pubid=1015
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at www.fastmr.com
or call us at 1.800.844.8156.